INTERLEUKIN-33

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: National Cancer Institute and 4 more

Animals2

Outcomes

Organoid formation

upin mouse cells1

1 study

INTERLEUKIN-33 increases organoid formation in mouse cells.
“promotes formation of organoids with Trp53 knockdown”
Cellswith Trp53 knockdownmammary epithelial cells
Divergent aging of nulliparous and parous mammary glands reveals IL33+ hybrid epithelial cells
Nature communications21 Jan 2026

Cell cycle regulation

upin mouse cells1

1 study

INTERLEUKIN-33 induces cell cycle regulation in mouse cells.
“IL33 treatment of mammary epithelial cells from young mice phenocopies aged nulliparous epithelial cells, induces proliferation”
Cellsmammary epithelial cells
Divergent aging of nulliparous and parous mammary glands reveals IL33+ hybrid epithelial cells
Nature communications21 Jan 2026